Imaging-detected immune-related adverse events may serve as an early indicator of improved survival in patients with advanced biliary tract cancer receiving durvalumab-based chemotherapy.
Researchers found that these radiologically identified events, many of which occur without symptoms, could help clinicians identify patients more likely to benefit from treatment.
In the study, 85.7% of imaging-detected irAEs emerged within 90 days of starting therapy. Only 35.7% of patients with such findings experienced related clinical symptoms.
Despite often going unnoticed, the presence of imaging-detected irAEs was linked to significantly better outcomes. In multivariate analysis, these findings independently predicted improved overall survival and progression-free survival.
Median overall survival reached 23.0 months among patients with imaging-detected irAEs, compared with 12.0 months for those without such findings.
The study suggests routine imaging surveillance may provide information beyond disease assessment alone, serving as an early marker of patients whose tumors are responding more effectively to durvalumab-based treatment.